Trevi Therapeutics, Inc. (TRVI)
$
13.01
+0.82 (6.30%)
Key metrics
Financial statements
Free cash flow per share
-0.3963
Market cap
1.7 Billion
Price to sales ratio
11.4 Thousand
Debt to equity
0.0043
Current ratio
21.9333
Income quality
0.9597
Average inventory
0
ROE
-0.3123
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine aimed at treating serious neurologically mediated conditions. The company is focused on advancing Haduvio through its phase IIb/III clinical trial for the management of chronic pruritus and chronic cough associated with idiopathic pulmonary fibrosis. As it progresses in its endeavors, the operating expenses amount to $51,524,000.00 encompassing various operational costs incurred throughout its research and development activities. The cost of revenue for the company is $0.00 showcasing its production and operational expenses necessary to sustain its clinical programs. In its financial reports, the company indicated a net loss of -$47,911,000.00 reflecting the challenges faced in its operations as it strives to bring innovative treatments to market. Additionally, the earnings per share (EPS) is reported at -$0.47 providing insight into the company's profitability on a per-share basis. With a gross profit of $0.00 the company underscores its profitability from core operations, despite the existing financial hurdles. The stock of Trevi Therapeutics is affordable at $8.15 making it suitable for budget-conscious investors looking to venture in this clinical landscape. Notably, the stock has a high average trading volume of 1,892,731.00 indicating strong liquidity that can benefit traders and investors alike. With a market capitalization of $1,668,272,287.00 the company is classified as a small-cap player within the biopharmaceutical sphere. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape with its innovative approaches to treatment. Additionally, it belongs to the Healthcare sector, driving innovation and growth through its commitment to addressing unmet medical needs in the realm of serious neurologically mediated conditions.
Is Trevi Therapeutics, Inc. (TRVI) a good investment?
Investing in Trevi Therapeutics, Inc. (TRVI) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Trevi Therapeutics, Inc. (TRVI)'s stock forecast?
Analysts predict Trevi Therapeutics, Inc. stock to fluctuate between $3.47 (low) and $14.39 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Trevi Therapeutics, Inc.'s market capitalization?
As of 2025-12-19, Trevi Therapeutics, Inc.'s market cap is $1,668,272,287, based on 128,229,999 outstanding shares.
How does Trevi Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Trevi Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Trevi Therapeutics, Inc. (TRVI) stock?
To buy Trevi Therapeutics, Inc. (TRVI) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for TRVI. Place an order (Market, Limit, etc.).
What is the best time to invest in Trevi Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Trevi Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.47 | Growth: 62.07%.
Where can I find Trevi Therapeutics, Inc.'s investor relations reports?
Visit https://www.trevitherapeutics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Trevi Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Trevi Therapeutics, Inc. stock?
All-time high: $14.39 (2025-12-10) | All-time low: $0.46 (2022-02-22).
What are the key trends affecting Trevi Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth NEW HAVEN, Conn. , Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that David Hastings will assume the role of Chief Financial Officer effective January 6, 2026.
seekingalpha.com
Trevi Therapeutics (TRVI) is initiated with a "Buy" rating, driven by its lead asset Haduvio's advancement toward phase 3 testing for chronic cough in IPF. Company's Haduvio demonstrated statistically significant efficacy in phase 2b CORAL study [IPF] and phase 2a RIVER [RCC], with a differentiated dual central/peripheral mechanism of action. The company is well-capitalized, with $194.9M in cash and a projected runway into 2028, supporting upcoming pivotal trials.
seekingalpha.com
Trevi Therapeutics, Inc. ( TRVI ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Jennifer Good - Co-Founder, CEO, President, Interim Principal Financial Officer & Director James Cassella - Chief Development Officer Farrell Simon - Chief Commercial Officer Conference Call Participants Ryan Deschner - Raymond James & Associates, Inc., Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Judah Frommer - Morgan Stanley, Research Division Serge Belanger - Needham & Company, LLC, Research Division Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division William Wood - B. Riley Securities, Inc., Research Division Kaveri Pohlman - Clear Street LLC Presentation Operator Good afternoon, and welcome to the Trevi Therapeutics Third Quarter 2025 Earnings Conference Call.
prnewswire.com
Fireside Chat with Management on Tuesday, November 11, 2025, at 3:20 p.m. ET NEW HAVEN, Conn.
prnewswire.com
Professor Philip Molyneaux will give an oral presentation on the key efficacy and safety results from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) Associate Professor Imran Satia will give a poster presentation on the patient-reported outcomes from the Phase 2a RIVER trial of nalbuphine ER for the treatment of patients with refractory chronic cough (RCC) NEW HAVEN, Conn. , Oct. 8, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the acceptance of two abstracts for presentation at the CHEST 2025 Annual Meeting, to be held from October 19 to 22 in Chicago, Illinois.
prnewswire.com
NEW HAVEN, Conn. , Sept. 18, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that data from the Phase 2a RIVER trial of nalbuphine ER for the treatment of patients with RCC, will be highlighted in two poster presentations at the European Respiratory Society (ERS) Congress 2025.
seekingalpha.com
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:05 PM EDT Company Participants Jennifer Good - Co-Founder, CEO, President, Interim Principal Financial Officer & Director Farrell Simon - Chief Commercial Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst Welcome to this session of the Morgan Stanley Global Healthcare Conference. I'm excited to welcome the team from Trevi.
prnewswire.com
NEW HAVEN, Conn. , Aug. 28, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in September.
seekingalpha.com
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants g - Corporate Participant e - Corporate Participant Farrell Simon - Chief Commercial Officer James V. Cassella - Chief Development Officer Jennifer L.
prnewswire.com
NEW HAVEN, Conn. , July 29, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in August.
See all news
